Endothelial cell-derived nidogen-1 inhibits migration of SK-BR-3 breast cancer cells by Ferraro, DA et al.
Ferraro et al. BMC Cancer          (2019) 19:312 
https://doi.org/10.1186/s12885-019-5521-8RESEARCH ARTICLE Open AccessEndothelial cell-derived nidogen-1 inhibits
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Background: The tumour microenvironment is a critical regulator of malignant cancer progression. While
endothelial cells have been widely studied in the context of tumour angiogenesis, their role as modulators of
cancer cell invasion and migration is poorly understood.
Methods: We have investigated the influence of endothelial cells on the invasive and migratory behaviour of
human cancer cells in vitro.
Results: Upon exposure to culture supernatants of endothelial cells, distinct cancer cells, such as SK-BR-3 cells,
showed significantly increased invasion and cell migration concomitant with changes in cell morphology and gene
expression reminiscent of an epithelial-mesenchymal transition (EMT). Interestingly, the pro-migratory effect on SK-
BR-3 cells was significantly enhanced by supernatants obtained from subconfluent, proliferative endothelial cells
rather than from confluent, quiescent endothelial cells. Systematically comparing the supernatants of subconfluent
and confluent endothelial cells by quantitative MS proteomics revealed eight candidate proteins that were secreted
at significantly higher levels by confluent endothelial cells representing potential inhibitors of cancer cell migration.
Among these proteins, nidogen-1 was exclusively expressed in confluent endothelial cells and was found to be
necessary and sufficient for the inhibition of SK-BR-3 cell migration. Indeed, SK-BR-3 cells exposed to nidogen-1-
depleted endothelial supernatants showed increased promigratory STAT3 phosphorylation along with increased cell
migration. This reflects the situation of enhanced SK-BR-3 migration upon stimulation with conditioned medium
from subconfluent endothelial cells with inherent absence of nidogen-1 expression.
Conclusion: The identification of nidogen-1 as an endothelial-derived inhibitor of migration of distinct cancer cell
types reveals a novel mechanism of endothelial control over cancer progression.
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The tissue microenvironment is critical for normal devel-
opment and homeostasis. Considering normal breast tis-
sue, for example, mouse mammary epithelial cells isolated
from mid-pregnancy mammary glands form acinus-like
structures if grown on a gel of reconstituted basement
membrane and differentiate to secrete milk proteins [1, 2].
However, when the same cells are cultured on tissue cul-
ture plastic, they rapidly suspend their milk production.
Hence, normal tissue function strongly depends on its© The Author(s). 2019 Open Access This artic
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the physiological processes in normal tissue, the micro-
environment exerts regulatory control during tumour de-
velopment and progression [3, 4]. In the state of the art,
tumours are considered organ-like systems consisting of
proliferating tumour cells and of various types of resident
and recruited stromal cells that affect tumour growth and
malignant behaviour [5]. On one hand, a variety of cells of
the tumour stroma, including fibroblasts, endothelial cells,
pericytes and immune cells, have been shown to support
tumour cell proliferation, tumour angiogenesis, escape
from immune surveillance and metastasis [6–9]. On the
other hand, certain tumour microenvironments restrict
tumour progression by repressing tumour cell migrationle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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tions of cancer-associated fibroblasts (CAFs) [11] and
tumour-infiltrating immune cells [12] have been largely
studied, the role of endothelial cells as regulators of cancer
cell behaviour is poorly understood.
Endothelial cells are the major players in angiogenesis,
which is one of the hallmarks of cancer progression [13, 14].
A critical step in this process is the activation of quiescent
endothelial cells by pro-angiogenic growth factors, referred
to as “the angiogenic switch”, which induces a cell biological
programme leading to the formation of new blood vessels
[15–17]. Angiogenesis has been proposed to be rate limiting
for tumour growth, and anti-angiogenic therapies have been
established and are routinely used in clinics to treat cancer;
however with rather limited efficacy [18]. Endothelial cells
have also attracted attention as important regulators of or-
ganogenesis and as niches for stem cell maintenance in vari-
ous tissues, such as brain, liver and pancreas [19–22]. In
normal tissue, endothelial cells are critical for tissue homeo-
stasis [23]. They are among the longest-living cells in the
body remaining quiescent over years. Normal quiescent
endothelial cells suppress local hyperplasia, angiogenesis and
inflammation, yet they enhance these processes when they
are dysfunctional. Endothelial cells might exert a similar ef-
fect during tumour growth and progression, not simply by
serving as static structural cells of perfused vessels but by ac-
tively modulating the tumour microenvironment and thus
tumour cells, which may have profound effects on cancer
fate. For example, several tumour-promoting factors origin-
ating from endothelial cells have been shown to increase
cancer cell proliferation [24].
Here, we speculate that endothelial cells depending on
their physiological state may also be able to affect tumour
cell invasion and migration by releasing stimulatory or in-
hibitory factors. With the demonstration of the anti-
migratory effect of endothelial cell-derived nidogen-1 on
SK-BR-3 breast cancer cells we add nidogen-1 to the regula-
tors of endothelial control over cancer cell migration.
Methods
Materials and reagents
The human anti-Paxillin antibody was purchased from
BD (cat. Num. 610,052), the anti-ZO-1 from Zymed (cat.
Num. 617,300), the anti-FN1 and anti-GAPDH from
Sigma (cat. Num. F-3648, cat. Num. G-8795), anti-Actin
from Santa Cruz (cat. Num sc-1616), anti-VE-Cadherin
from ABcam (ab33168), anti-Nidogen-1 from R&D (cat.
Num. MAB2570–100), anti-pSTAT3 and anti-Stat3 from
Cell Signaling (cat. Num. 9131, 9132), anti-CD31 from
BD Pharmigen (cat. Num. 550,274), anti-phospho Histone
3 from Millipore (cat. Num. 06–570). Fluorescently la-
beled secondary antibodies and anti-Phalloidin-568 were
purchased from Invitrogen, DAPI was obtained from
Sigma. FLLL31 was purchased from Sigma (cat. Num.F9057). RhNID1 (cat. Num.: 2570-ND-050) and rhBGN1
(cat. Num. 2667-CM-050) were purchased from R&D,
Minneapolis, MN, USA.
Cell culture
Primary human umbilical vein endothelial cells
(HUVECs; PromoCell, Heidelberg, Germany) and pri-
mary human dermal microvascular endothelial cells
(HDMECs; PromoCell, Heidelberg, Germany) were ex-
panded in endothelial growth medium (EGM) and sup-
plements (Lonza, Basel, Switzerland) on 1.5%
gelatine-coated plates. The cancer cell lines SK-BR-3,
MCF7, PC-3 and H460 were cultured in DMEM with
10% FBS (Sigma Aldrich, Buchs, Switzerland).
To prepare endothelial cell-conditioned medium
(EC-CM), confluent HUVEC monolayers were detached,
and the cells were plated onto new cell culture dishes of
the same diameter in EGM. To prepare conditioned
medium from confluent HUVEC 9/10 of the total cell
number was seeded for expansion. To obtain condi-
tioned medium from subconfluent HUVEC 1/10 of the
total cell number was plated. After 24 h of culturing,
medium was changed with conditioning medium (M199
medium (Sigma Aldrich, Buchs, Switzerland) containing
2% FBS supplemented with 1% penicillin, 0.1% glutam-
ine, 4 μg/ml bovine pituitary extract (Thermo Fisher,
Waltham, MA, USA) and 8 U/ml heparin). After a con-
ditioning time of 24 h the supernatant was collected, cell
debris were removed and the conditioned medium was
stored at − 80 °C. For the experiments the cancer cell
lines were expanded for 24 h, then the expansion
medium was removed and the cancer cells exposed to
the HUVEC conditioned medium for 4 days.
Immunofluorescence microscopy analysis
Cells, plated and treated on glass coverslips, were
washed and fixed in 4% PFA for 20 min at RT, perme-
abilized with 0.5% NP40 in PBS for 5 min, washed and
blocked with 3% BSA in PBS-Triton for 1 h at RT. The
cells were then incubated with the primary antibody
over night at 4 °C. Fluorescently labeled secondary anti-
bodies were added together with DAPI 1 μg/ml for 1 h
in the dark. Cells were washed 5 times, mounted and
imaged on a fluorescent microscope (Leica DMI4000).
siRNA interference
Endothelial cells were transfected with 4 siRNAs for
each target (siGENOME Human SMARTpool, Dharma-
con Lafayette, Colorado, USA) with Lipofectamine 3000
(Invitrogen, Thermo Fisher Waltham, MA, USA) ac-
cording to the manufacturer’s instructions. The siRNA
sequences are as follows: NID1: GGGCGAACCUG-
CUAUGAUA, GAAGGUUUAUUAUCGAGAA, UAAC-
CUGGAUCGAAUAGAA, and CCUUCAUAACUGC
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UGAAUGAACUCCACCUAGA, CCAAAGAGAUCUC
CCCUGA, and GAACAACGACAUCUCCGAG; HSPG2:
GCGCUGCGAUGGUGACUUU, CAACACACACCAC-
GAGCUA, GAGCUAUGUGAAUGCAAU, and ACG-
GUGGGAAGUUGCGAUA; CLU: GAUAAAGACU
CUCAUAGAA, GAAAGAGGAUGCCCUAAAU, GGAA-
GUAAGUACGUCAAUA, and GUAGAAGUCUCCAG-
GAAGA; C1QTNF5: GCGAAUCCAUUGCCUCUUU,
UGAACGAGCAGGGACAUUA, GGGCCAGCCUGCA-
GUUUGA, and UGACUACAUUGGCAUCUAU; CYR61:
GGGCAGACCCUGUGAAUAU, GGCCAGAAAUGUA
UUGUUC, GGUCAAAGUUACCGGGCAG, and GCAG-
CAAGACCAAGAAAUC; TIE1: GGGAAGCCUC-
CUACCCUUA, GAAGUUCUGUGCAAAUUGG, CAAC
AUGGCCUCAGAACUG, and UCGAAACUGUGAC-
GAUGAA; VWF: GGACAGAUCAUGACACUGA,
GGAAGACCCUGUGGACUUU, GAAGAGGCCUGCA-
CUCAGU, and GGUCACAUCUUCACAUUCA. After
72 h, the transfection medium was changed, and a second
transfection was performed. Twenty-four hours after the
second siRNA transfection, the cells were used for
experiments.
Migration and transendothelial migration assay
A total of 50′000 SK-BR-3 cells were plated into
Boyden-Chamber inserts with 8 μm pore size (BD Fal-
con, Corning Tewksbury MA, USA) in 200 μl M199
(Sigma Aldrich, Buchs, Switzerland) 2% FBS medium;
the bottom chamber was filled with 800 μl of M199 20%
FBS medium. After a migration time of 18 h, the cells
were fixed with 4% paraformaldehyde in PBS. Cells that
had not crossed the membrane were removed, and cells
on the bottom of the insert membrane were stained with
DAPI (1 μg/ml), visualized with a Leica DMI4000 fluores-
cence microscope and quantified using ImageJ software.
The trans-endothelial migration assay was performed as
previously described [25]. Briefly, a total of 15′000 Cell-
Trace CFSE (Invitrogen, Thermo Fisher Waltham, MA,
USA)-labelled SK-BR-3 cells were seeded onto a confluent
HUVEC monolayer and incubated over 48 h in 5% CO2 at
37 °C without a serum gradient. After removal of
non-migrated cells, cells that crossed the HUVEC mono-
layer were fixed with 4% paraformaldehyde, visualized and
quantified as described above. Immunofluorescence and
immunoblotting were performed as previously described
[26]. All experimental conditions were tested and analysed
in three replicates and each condition was tested in bio-
logical triplicates.
RNA isolation and RT-PCR
Total RNA was prepared with Tri-Reagent (Sigma Al-
drich, Buchs, Switzerland) and reverse-transcribed with
ImProm-II™ reverse transcriptase (Promega, Madison,Wisconsin, USA). Transcripts were quantified using
SYBR-green PCR Master Mix in a StepOnePlus PCR sys-
tem (Applied Biosystems, Foster City, California, USA).
Real-time PCR reactions were performed in triplicate,
and fold-induction was calculated using the comparative
Ct method (ΔΔCt) normalized to ribosomal protein L19
expression. The following primers (sequence 5′-3′) were
used: human nid1: TCTACGTCACCACAAATGGCA;
human hspg2: GTGTGGTGTTCATCAAGGAGC; hu-
man nid2: GAAACGCAGTATGTGGACTATGA; human
cyr61: GGTCAAAGTTACCGGGCAGT; human vwf:
CCGATGCAGCCTTTTCGGA; human clu: CCAAT-
CAGGGAAGTAAGTACGTC; human c1qtnf5: AAC-
GAGCAGGGACATTACGAC; human tie1: AAGC
AGACAGACGTGATCTGG; human bgn: CAGT
GGCTTTGAACCTGGAG; and human rpl: GATGCC
GGAAAAACACCTTG.
Immunoblotting analysis
Cells were lysed with 0.5M Tris-Hcl ph 6.8, 10% SDS, gly-
cerol and the lysates boiled for 5min. Lysates were nor-
malized for equal amount of protein and loaded onto
SDS-polyacrylamide gels and transferred to nitrocellulose
membranes (Whatman Protran). Blots were sequentially
incubated with 5% milk, the primary antibody (1:1000)
overnight, and the HRP-labeled secondary-antibody
for 1 h at room temperature. Signals were revealed
with Upti-Light™ chemiluminescence reagent (Uptima)
and detected with X-Ray films.
Stable isotope labelling by amino acid in cell culture
(SILAC) of HUVEC
HUVECs were cultured in custom-made EGM-2 without
arginine and lysine (Lonza), with the addition of SILAC
amino acids (13C6 L-arginine and
2H4 L-Lysine for the
“SILAC medium” or 13C6
15N4 L-arginine and
13C6
15N2
L-Lysine for the “SILAC heavy”) (Cambridge Isotope La-
boratories) until more than 97% of SILAC amino acids
were incorporated into proteins.
Labelled “heavy” and “medium” cells were split either
sub-confluent or confluent (ratio of sub-confluent to
confluent being 1:20) for 3 days (until the confluent cells
had reached 100% confluency), washed in PBS with Ca2+
and Mg2+, and incubated in EBM-2™ medium (Lonza,
Basel, Switzerland) for 4 h. The supernatants were col-
lected and spun at 4 °C (300 g for 10 min, followed by
2000 x g for 10 min and 10,000 x g for 30 min). The cells
were counted and the “heavy” supernatant coming from
the confluent cells was pooled together with the
“medium” supernatant coming from the sub-confluent
cells (forward experiment) and vice versa (reverse ex-
periment), adapting the volume to the corresponding
cell number. Proteins were extracted using Strataclean
resin (Agilent Technologies) as previously described
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ing buffer, Life Technologies) supplemented with 0.1M
DTT and separated on a 4–12% NuPAGE Novex
Bis-Tris gel (Life Technologies). Each gel lane was cut in
seven slices and proteins were in-gel digested with tryp-
sin. Peptides were loaded onto Empore-C18 StageTips
and eluted with 80% ACN and 0.5% acetic acid.
Mass spectrometry (MS) analysis of secretome
Digested peptides were separated by nanoliquid chroma-
tography (Easy nLC, Thermo Fisher Scientific) coupled
on line to a linear trap quadrupole (LTQ)-Orbitrap Elite
mass spectrometer (Thermo Fisher Scientific) via a
nanoelectrospray ion source (Nanospray Flex Ion
Source, Thermo Fisher Scientific). Peptides were loaded
onto a 20 cm fused silica emitter (New Objective)
packed with C18-AQ, 1.9 μm resin (Dr Maisch GmbH)
and eluted with 5–25% solvent (80% ACN, 0.5% acetic
acid) over 90 min (200 nl/min). Full scan MS spectra
were acquired in the Orbitrap analyzer with a resolution
of 120,000 at 400 Th, and a target value of 106 charges.
The 10 most intense ions were selected for high collision
dissociation fragmentation with a target value of 40,000
charges and acquired in the Orbitrap with resolution of
15,000 at m/z 400 Th. Data were acquired with Xcalibur
software (Thermo Fisher Scientific).MS data quantification and analysis
The relative quantification based on SILAC labelling was
performed by processing the RAW MS files with Max-
Quant version 1.4.1.6 [28]. Proteins and peptides were
identified using the Andromeda search engine [29]
against the human UniProt database (release-2012 01,
88,847 entries). To search for precursor and fragment
ions, an initial maximal mass deviation of 7 ppm and 20
ppm, respectively, was required. Trypsin with full en-
zyme specificity and only peptides with a minimum
length of 7 amino acids were selected. A maximum of
two missed cleavages was allowed. Carbamidomethyla-
tion (Cys) was set as fixed modification, while Oxidation
(Met) and N-acetylation as variable modifications. For
protein and peptide identification, we required a max-
imum false discovery rate (FDR) of 1%. The “requantify”
option was enabled.
Data analysis and normalization
Statistical analysis and annotation of the MS data were
performed using the Perseus module of MaxQuant ver-
sion 1.4.17.2. The reverse and contaminant hits from the
MaxQuant output files were excluded from the analysis.
Only proteins identified with at least 1 unique peptide
and quantified with a minimum of two ratio counts were
considered for the analysis.For each experiment (forward and reverse), the SILAC
ratios (sub-confluent/confluent cells) were transformed
using the binary logarithm (log2) and normalised by
subtracting the median value. Proteins were considered
up or down-regulated if the SILAC ratio was higher than
one standard deviation from the mean of the calculated
ratios in both replicate experiments. Protein annotations
were added based on the Uniprot ID of each entry (GO
and KEGG categories).
Human phospho-kinase antibody array
The protein lysates from 10′000’000 cells were analysed
in a sandwich immunoassay with membrane-bound cap-
ture antibodies and biotinylated phospho-specific detec-
tion antibodies on the human phospho-kinase antibody
array (ARY003B, R&D System, Minneapolis, MN, USA)
according to the manufacturer’s instructions. The spot
signals were quantified using ImageJ software.
Results
Endothelial cells influence cancer cell invasion and
migration
We set out to elucidate the influence of endothelial cells on
the regulation of cancer cell invasion and migration. We first
employed an in vitro co-culture system where cancer cell
lines were cultured on a tight layer of commercially available
primary human endothelial cells. Upon co-culturing several
cell lines started to trans-migrate the endothelial cell layer
(Fig. 1a; Additional file 1 Figure S1A). To dissect the mecha-
nisms and to clarify whether secreted factors from endothe-
lial cells are sufficient to influence the migratory potential of
the cancer cells without cell-cell contact, we pre-exposed the
cancer cell lines to human umbilical vein endothelial cells
conditioned medium (HUVEC-CM) for 4 days. Upon expos-
ure to HUVEC-CM, distinct cancer cell lines exhibited a sig-
nificantly increased ability to migrate following a serum
gradient in a modified Boyden-chamber assay (Fig. 1b). The
most significant increase in cell migration could be seen
with SK-BR-3 human breast cancer cells, and we decided
to use this cell line as a model system for further experi-
mentation. PC-3 prostate cancer cells showed the same
response to HUVEC-CM (Fig. 1a, b), while MCF7 breast
cancer cells and H460 lung cancer cells did not show any
change in their migratory potential.
We next assessed whether the observed increased mi-
gratory potential of SK-BR-3 cells was associated with
changes in cell morphology and expression of differenti-
ation markers. After exposure to HUVEC-CM, SK-BR-3
cells showed a more elongated morphology with an in-
creased number of membrane protrusions (Fig. 1c,
upper panel). Additionally, these cells displayed an in-
crease in focal adhesions analysed by paxillin staining
and a cytoskeletal re-organization of epithelial cortical
actin to mesenchymal stress fibres as shown by
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Fig. 1 Endothelial cells influence the phenotype and migratory potential of cancer cells. a CFSE fluorescently labelled cancer cell lines were
plated on a tight HUVEC monolayer on the inner surface of a Boyden migration chamber for migration through the endothelial cell layer. After
48 h, the cells remaining in the insert of the chamber were removed, and the number of migrated cancer cells was quantified by fluorescence
microscopy and compared to its own control (migration in absence of endothelial monolayer) . All experimental conditions were tested in three
replicates and each condition in biological triplicates. (***p ≤ 0.0001, *p ≤ 0.05 versus control by unpaired student’s t-test, error bar: standard error
of the mean). b Different cancer cell lines were exposed to human umbilical vein endothelial cell (HUVEC)-conditioned medium for 4 days. After
exposure to the HUVEC supernatant, cancer cell migration was evaluated using a Boyden chamber migration assay. The migration rate of each
cell line exposed to the HUVEC-conditioned medium was compared to its own control in non-conditioned medium (**p ≤ 0.01, *p ≤ 0.05 versus
ctrl by unpaired student’s t-test). c SK-BR-3 cell morphology was visualized by phase contrast imaging (top) after exposure to unconditioned or
HUVEC-conditioned medium. Expression of actin stress fibres (phalloidin), focal adhesions (paxillin) and tight junctions (ZO-1) was analysed by
immunofluorescence staining (middle, bottom). d SK -BR-3 cells were exposed to unconditioned (ctrl) or conditioned media derived from
confluent or subconfluent HUVEC and HDMEC cultures for 4 days. The effect on the migration of SK-BR-3 cells was evaluated using a Boyden
chamber assay (**p≤ 0.05, ***p ≤ 0.001 versus ctrl by unpaired student’s t-test, error bar: standard error of the mean). e Expression of fibronectin
(FN1) was detected by immunofluorescent staining of SK-BR-3 cells after 4 days of exposure to unconditioned (ctrl) or conditioned medium
derived from confluent or subconfluent HUVEC cultures
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epithelial cobblestone growth pattern of the SK-BR-3
cells was disrupted, and tight junctions were dissolved as
visualized by the loss of ZO-1 from the plasma mem-
brane (Fig. 1c, lower panel). These findings suggest that
the factors secreted by cultured endothelial cells induced
an epithelial-mesenchymal transition (EMT)-like process
in SK-BR-3 cells that is associated with increased
SK-BR-3 cell migration and invasion, hallmarks of can-
cer cell aggressiveness [24]. While in control medium
MCF-7 shows an epithelial morphology similar to
SK-BR-3, the change of morphology and the ability to
migrate could not be observed in MCF-7 upon exposure
to HUVEC-CM (data not shown).
The tumour stromal microenvironment plays a dual role
either as a promoter [30] or as an inhibitor of cancer pro-
gression [31]. Endothelial cells might have a central regula-
tory function in tumour-stromal interaction depending on
their physiological state. Tumour-associated endothelial
cells [32, 33] are distinct from normal endothelial cells in
healthy tissue [34]. While normal endothelium stays in a
quiescent state, the proliferation rate of tumour-associated
endothelial cells is dramatically increased [32]. We mim-
icked these distinctions by defining the culture density of
HUVECs in vitro [35]. The quiescent endothelium of nor-
mal blood vessels is best represented by a confluent layer of
cultured endothelial cells. The activated, proliferating and
sprouting endothelium typical of active angiogenesis is best
embodied by a proliferating, subconfluent endothelial cell
culture [36]. We hypothesized that the quiescent and the
proliferating endothelial cell states could differentially affect
the migratory potential of cancer cells. To test this hypoth-
esis, supernatants were prepared from human dermal
microvascular endothelial cells (HDMEC) and from
HUVECs under confluent or subconfluent conditions
(Additional file 1 Figure S1B) and added to SK-BR-3 cells
for 4 days. Compared to SK-BR-3 cells cultured in uncondi-
tioned control medium, the supernatants from HDMECs
and HUVECs increased the migratory potential of
SK-BR-3. Notably, SK-BR-3 cells treated with supernatants
of subconfluent HDMECs and HUVEC cultures had a sig-
nificantly greater migratory potential than cells exposed to
supernatants of confluent cultures (Fig. 1d). Consistent with
the induction of a spindle shape cellular phenotype, depos-
ition of fibronectin, a component of the extracellular matrix
important for attachment and migration, by SK-BR-3 cells
was higher after exposure to supernatants of subconfluent
HUVECs than of confluent HUVECs (Fig. 1e).
These findings show that endothelial cells secrete fac-
tors that induce a change of morphology of distinct can-
cer cells such as SK-BR-3 in parallel with the induction
of an increased migratory potential. Moreover, these fac-
tors are dependent on the growth and activation status
of endothelial cells. Since HDMEC and HUVECsupernatant had a very similar effect on the migratory
ability of SK-BR-3 cells we decided to focus further ex-
periments on the interaction of SK-BR-3 with HUVEC.Endothelial-derived nidogen-1 inhibits migration of SK-
BR-3 cells
To identify factors released from endothelial cells that
control cancer cell migration, we compared the secre-
tome of confluent with that of subconfluent HUVEC
cultures by MS-SILAC proteomics [27, 37] (Fig. 2a,
Additional file 2 Table S1). The levels of the vast major-
ity of the proteins in the two conditioned media were
similar. Only eight proteins were found at significantly
higher levels in the supernatants of confluent compared
to subconfluent HUVEC cultures. These proteins were
nidogen-1, biglycan, hspg2, clusterin, complement c1q
tumour necrosis factor protein 5, Cyr61, Tie1 and von
Willebrand factor. Since conditioned medium from con-
fluent HUVECs induced less migration of cancer cells
than medium from subconfluent HUVECs, we suspected
the identified proteins to be potential repressors of can-
cer cell migration. We tested this hypothesis by
siRNA-mediated depletion of each candidate gene in
HUVECs. Supernatants of the target gene-depleted
HUVECs were applied to SK-BR-3 cells for 4 days before
testing the SK-BR-3 cell migratory potential. Among the
eight candidates only the downregulation of nidogen-1
expression in confluent HUVECs was able to signifi-
cantly increase cancer cell migration (Fig. 2b). Depletion
of the target gene was shown by real-time-PCR (Fig. 2c).
These results suggest that nidogen-1 might be respon-
sible for the anti-migratory activity in the supernatant of
confluent HUVECs.
Nidogen-1 is a member of the nidogen family of basal
membrane glycoproteins. Both nidogen-1 and nidogen-2
are essential components of the basal membrane that
structure it by connecting networks formed by collagens
and laminins. Furthermore, nidogen-1 and nidogen-2
play a role in the interactions of the extracellular matrix
with the cells [38].
In our experimental system, only the expression of
nidogen-1 was dependent on the HUVEC growth and
activation status and depletion of nidogen-1 was not com-
pensated by over-expression of nidogen-2 (Fig. 2d, e). To
assess whether nidogen-1 was exclusively expressed by
endothelial cells, we tested its protein expression in con-
fluent and subconfluent HUVECs and in SK-BR-3 and
PC3 cancer cells (Fig. 3a). Confirming the MS-SILAC ana-
lysis, confluent HUVECs expressed significantly higher
amounts of nidogen-1 than subconfluent HUVECs. More-
over, the tested cancer cells did not express nidogen-1 at
levels comparable to HUVECs. These data raise the possi-
bility that the inhibitory effect of confluent HUVECs on
Fig. 2 Identification of candidate proteins by SILAC MS proteomic analysis of the endothelial secretome. a The protein levels in confluent and
subconfluent HUVEC cells were accurately measured with SILAC using the MaxQuant software. The proteins are depicted in a scatter plot.
Highlighted in the square are the proteins with a SILAC ratio≥ 1.5 SD from the mean of the calculated ratio in each replicate experiment, A and
B. These proteins were secreted at higher levels by confluent HUVEC. b The candidate proteins identified by SILAC MS analysis were silenced with
siRNAs in HUVECs kept under confluent growth conditions. The migratory potential of SK-BR-3 cells exposed to conditioned medium of HUVECs
with silenced proteins was evaluated using a Boyden chamber migration assay and compared to controls (*p≤ 0.05 versus ctrl by unpaired
student’s t-test). c The efficiency of siRNA knockdown was analysed for each candidate gene that was identified by SILAC. The mRNA expression
levels were evaluated by quantitative RT-PCR analysis of confluent HUVECs after siRNA-mediated knockdown of the respective gene. d Gene
expression of NID1 and NID2 was evaluated by quantitative RT-PCR analysis of HUVECs plated in a confluent or subconfluent monolayer. e Gene
expression of NID1 and NID2 was determined by quantitative RT-PCR analysis of HUVECs plated in a confluent monolayer after siRNA-mediated
knock-down of NID1
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nidogen-1.
The secretion of fibronectin, a known marker of EMT,
was increased in SK-BR-3 cells cultured with conditioned
medium of subconfluent HUVEC (Fig. 1e, Fig. 3b). However,
addition of recombinant nidogen-1 reversed the expression
of fibronectin in a dose-dependent manner (Fig. 3b). Fur-
thermore, the pro-migratory effect of the conditioned
medium of subconfluent HUVEC on SK-BR-3 cells was sig-
nificantly reduced in the presence of recombinantnidogen-1, recapitulating the difference observed between
the supernatants of confluent and subconfluent endothelial
cells (Fig. 3c).
The basal membrane with nidogen-1 as one of its
components serves as a strong barrier for cancer cells.
Other basal membrane components, such as hspg2, have
already been shown to exert an anti-migratory function
[39]. In fact, MS-SILAC analysis revealed hspg2 and
biglycan to be more abundant in the supernatant of con-
fluent HUVECs than in that of subconfluent HUVECs
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Fig. 3 Nidogen-1 blocks endothelial-induced migration of cancer cells. a The endogenous expression of nidogen-1 (NID1) protein was
determined by western blot analysis in HUVECs kept under confluent or subconfluent growth conditions and in the cancer cell lines SK-BR-3 and
PC3. Actin was used as a loading control. b Fibronectin-1 (FN1) expression was evaluated by immunoblotting analysis in SK-BR-3 cells exposed to
conditioned medium derived from subconfluent HUVECs for 4 days or with increasing concentrations of recombinant nidogen-1 (0, 0.01, 0.05, 0.2,
and 0.5 μg/ml). GAPDH was used as a loading control. c SK-BR-3 cells were treated for 4 days with unconditioned medium or conditioned
medium derived from subconfluent HUVECs with or without recombinant human nidogen-1 (rhNID1 1 μg/ml), with or without human biglycan
(rhBGN 1 μg/ml) or in combination. After treatment, the migratory capacity of the cells was determined using a modified Boyden chamber
migration assay (**p≤ 0.01, *p ≤ 0.05 versus control by unpaired student’s t-test)
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cantly increased SK-BR-3 cell migration. However, re-
combinant biglycan reduced cancer cell migration to a
similar extent than nidogen-1. Furthermore, the combin-
ation of recombinant nidogen-1 and biglycan had an
additive effect on SK-BR-3 cell migration (Fig. 3c).
These results suggest that nidogen-1 from HUVECs
cultured at confluence inhibits SK-BR-3 migration, sug-
gesting that nidogen-1 might play a role in the signal-
ling between endothelial and cancer cells to control
cancer cell migration.
STAT3 signalling is a main driver of endothelial-
dependent cancer cell migration
Cell migration and metastasis is a multistep process that
involves the activation of many transcription factors and
signalling pathways, mostly triggered by the tumour
microenvironment [14, 40],. To determine which signal-
ling pathways could be involved in nidogen-1-dependent
migration, we screened a series of known signalling ef-
fector proteins for their activation by phosphorylation
on a phosphoprotein array. SK-BR-3 cells were exposedto conditioned medium of confluent nidogen-1-depleted
HUVECs (siNID1) or to conditioned medium of conflu-
ent HUVECs transfected with control siRNA (siCtrl) or
to normal growth medium. Cell lysates of SK-BR-3 cells
exposed to these three conditions were analysed on a
human phosphoprotein array to screen for site-specific
phosphorylation of 43 kinases and their effector pro-
teins. Most of the proteins exhibited absent or un-
changed phosphorylation levels. However, with the
nidogen-1-depleted conditioned medium of confluent
HUVECs the pSTAT3 (Y705) signal was markedly in-
creased in SK-BR-3 cells as compared to control super-
natants (Fig. 4a-c), suggesting an inhibitory effect of
nidogen-1 on STAT3 phosphorylation.
STAT3 signalling has been shown to promote cancer
cell migration in response to environmental stimuli [41].
Consistent with the results of the phosphoprotein array,
immunoblotting analysis showed that STAT3 phosphoryl-
ation levels are higher after the stimulation of SK-BR-3
cells with the supernatant of the subconfluent HUVEC
culture than that of the confluent HUVEC culture. A time
course displayed increasing phosphorylation over time,
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targeting NID1 (siNID1) or control siRNA. b Cell lysates from SK-BR-3 cells, SK-BR-3 cells with control siRNA and SK-BR-3 cells with siRNA knockdown of
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the background signal, the average of the duplicated spots was plotted (*p≤ 0.05 versus ctrl by unpaired student’s t-test). c The phosphorylation state of
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(0.5 μM) for 4 days (**p≤ 0.01 versus ctrl by unpaired student’s t-test)
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signalling as one of the main inducers of cancer cell mi-
gration stimulated by endothelial cells. In fact, blocking
STAT3 signalling with the specific JAK/STAT inhibitor
FLLL31 inhibited the pro-migratory effect on SK-BR-3
cells induced by stimulation with conditioned medium of
subconfluent HUVECs (Fig. 4e, f ). This inhibitory effect of
FLLL31 with a decrease in SK-BR-3 migration by 67% wasvery similar to the decrease observed with HUVEC con-
fluent conditioned medium by 70%. The decrease in
SK-BR-3 migration by rNID1 compared to migration in-
duced by HUVEC subconfluent conditioned medium was
35.5%. These results show that conditioned medium de-
rived from endothelial cells activates the promigratory
STAT3 signalling pathway and stimulates SK-BR-3 migra-
tion. Depletion of nidogen-1 from conditioned medium of
Ferraro et al. BMC Cancer          (2019) 19:312 Page 10 of 13confluent endothelial cells further enhances STAT3 activa-
tion and SK-BR-3 migration reflecting the situation of
conditioned medium from subconfluent endothelial cells
where nidogen-1 is inherently not expressed. Together the
data show that depending on their physiological state
endothelial cells exert a regulatory control over the migra-
tory potential of distinct cancer cells and a systematic mo-
lecular screen revealed nidogen-1 as a relevant endothelial
cell derived inhibitor of migration of these cancer cells.Discussion
The microenvironment plays a central role in cancer con-
trol [8, 30]. Here, we have delineated in well controllable
two-dimensional in vitro experiments how endothelial
cells, a main component of the tumour environment, in-
fluence important morphological features and functional
characteristics of cancer cells, such as EMT-like changes,
cell invasion and migration. We show that paracrine sig-
nals originating from endothelial cells can lead to in-
creased cell migration and trans-endothelial invasion of
distinct cancer cell lines. We have shown the effects of
conditioned medium derived from two commercially
available primary human endothelial cells, HUVEC and
HDMEC, on specific tumor cell lines suggesting a general
characteristic of endothelial cells, but we are aware that
we did not test the effect of primary tumor derived endo-
thelial cells on cancer cells in an in vivo three-dimensional
environment. While several of the tested cancer cell lines
responded to the endothelial stimuli with increased migra-
tory potential, others remained unresponsive. This finding
suggests that the endothelial microenvironment is not a
general modulator of tumour progression but needs to
match distinct features of the cancer cells, most likely
their transformation status and their responsiveness to
EMT-like changes.
Furthermore, we show that the ability of endothelial
cells to stimulate or to inhibit cancer cell migration is
dependent on the physiological status of endothelial
cells. Comparing the secretome of confluent, quiescent
HUVECs with that of subconfluent, proliferative
HUVECs by MS-SILAC analysis has revealed a number
of significantly more abundant proteins in the super-
natant of confluent HUVECs, thus representing poten-
tial inhibitors of tumour cell migration. Remarkably,
basal membrane and extracellular matrix proteins (nido-
gen-1, biglycan, cyr61, hspg2) were over-represented.
Supporting our hypothesis, hspg2 has been previously
described as an endothelial cell-derived inhibitor of can-
cer cell migration and metastasis [39]. However, the ac-
tual role of extracellular matrix proteins in cancer cell
invasion and migration has remained elusive. For in-
stance, biglycan has been reported to either induce can-
cer cell invasion [42] or to inhibit metastasis [43, 44].With this report we show that endothelial cell derived
nidogen-1 represses cancer cell migration.
Nidogen-1 belongs to a family of glycoproteins present
in the basal membrane of different organs, mainly in
blood vessels [45, 46]. The functional effects of
nidogen-1 in carcinogenesis however remain conflicting.
On one hand, a recent publication describes nidogen-1
as a promoter of metastasis to the lung in a breast can-
cer and melanoma model and high expression of
nidogen-1 to correlate with an unfavourable prognosis
in estrogen receptor negative breast cancer [47]. Also in
ovarian cancer, nidogen-1 has been shown to promote
EMT and metastasis [48]. On the other hand, the NID1
locus has been described in a genome-wide association
study to be linked with the risk of developing melanoma
with a decreased expression of nidogen-1 in nevi and
melanoma patients [49]. Loss of nidogen-1 by aberrant
promoter methylation has also been linked to develop-
ment of colon and stomach cancer [50], and also in
prostate cancer loss of nidogen-1 increased tumour
growth and metastasis [51]. In line with these reports
showing an inhibitory effect of nidogen-1 on cancer cell
migration and metastasis, using gain and loss of function
experiments we demonstrate that endothelial derived
nidogen-1 is an inhibitor of migration for certain cancer
cell types, such as SKBR-3 human breast cancer cells.
Since an adequate control protein is difficult to find, we
compared the inhibiton of migration by nidogen-1
against HUVEC subconfluent conditioned medium as a
control which might be viewed as a limitation of this ob-
servation. In parallel with the inhibition of migration the
expression of fibronection, a marker for EMT, is de-
creased in SK-BR-3 upon stimulation with nidogen-1.
While stromal derived nidogen-2 has previously been
shown to repress the number of metastases in a melan-
oma model [52] and its expression has also been shown
to inhibit metastasis in nasopharyngeal and oesophageal
carcinoma [53], equal expression of nidogen-2 in conflu-
ent and subconfluent HUVEC cells indicates that
nidogen-2 does not play any role in the endothelial con-
trol of SK-BR-3 breast cancer cell migration. This sug-
gests that the influence of the two nidogen isoforms
might be specific for the cancer cell type and should be
analysed separately with regard to the respective
tumour-stromal context.
We further show that conditioned medium derived
from endothelial cells activates the promigratory STAT3
signalling pathway and stimulates SK-BR-3 migration.
These effects are further enhanced in the absence of
nidogen-1, either by inherent absence of nidogen-1 in
conditionend medium from subconfluent endothelial
cells or by siRNA-mediated depletion of nidogen-1 from
endothelial cells. STAT3 signalling is well known to be
activated in cancer [54, 55] and is specifically involved in
Ferraro et al. BMC Cancer          (2019) 19:312 Page 11 of 13EMT, in the acquisition of a stem-cell-like phenotype
and in defining the premetastatic niche [56]. In our ex-
perimental system, STAT3 is the main signal transducer
leading to endothelial induced tumour cell migration, as
inhibition with the STAT3 signalling inhibitor FLLL31 is
sufficient to repress endothelial cell-dependent migra-
tion of SK-BR-3 cells. However, how STAT3 signalling
and cancer cell migration are induced by subconfluent
HUVEC medium, how nidogen-1 represses STAT3
phosphorylation and thus its signalling effector role, and
whether such repression is the only mode of action of
nidogen-1 in repressing cancer cell migration remain to
be resolved. Conditioned medium derived from subcon-
fluent or confluent HUVECs contains a variety of
growth factors, including several members of the EGF
and FGF families (data not shown). Nidogen-1 thus
might interfere with the ligand-receptor binding of
pro-migratory factors secreted by endothelial cells or by
direct signalling to the recipient cells. These mecha-
nisms warrant further investigation.
Conclusion
With the identification of nidogen-1 as an inhibitor of can-
cer cell migration, we characterized an endothelial
cell-derived regulator critical for malignant tumour pro-
gression. Proliferative endothelial cells are able to release
factors to induce cancer cell migration with the activation
of pro-migratory signals, such as STAT3. Quiescent endo-
thelial cells exert control over cancer cell migration by re-
leasing inhibitory factors such as nidogen-1. It appears that
these interactions are specific for distinct tumour types.
Published evidence [47] and our data suggest that
nidogen-1 might play a dual role in cancer cell migration
depending on the tumour type and the microenvironmental
context. The molecular details of the crosstalk between
endothelial cells and cancer cells, besides angiogenesis, offer
the opportunity to discover new therapeutic targets and to
develop new strategies for innovative therapies.
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